Overview
Q3 2024
Quarterly Results
Sep 30, 2024
Price
Change
MKT Cap
Volume
Corbus is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline encompasses two different approaches to oncology with different risk profiles: a next-generation Nectin -4 Antibody Drug Conjugate (ADC) and monoclonal antibodies that target integrins to inhibit activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts.
Sign up for email alerts
Be the first to receive breaking news
Sign up today
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa
Dr. Dominic Smethurst, MA MRCP
Chief Medical Officer
Dr. Smethurst, MA MRCP, joined Corbus as our Chief Medical Officer in February 2024. He has over twenty years of experience working with various pharmaceutical and biotechnology companies, clinical research institutions, and the
Sean Moran, CPA, MBA
Chief Financial Officer
Sean Moran, CPA, joined Corbus as a co-founder and Chief Financial Officer in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran
Christina Bertsch
VP of Human Resources
Christina Bertsch joined Corbus in April 2020. She has over 25 years of experience in human resources as both a management consultant and as an HR executive, primarily in the life sciences industry. Ms. Bertsch has significant
Alan Holmer
Chairman of the Board
Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and
View Full Bio
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa
View Full Bio
Anne Altmeyer, Ph.D.
Director
Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as the Chief Business Officer of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development
View Full Bio
Yong Ben, M.D., MBA
Director
Dr. Ben has over 25 years of medical experience in academia and pharmaceutical and biotech companies, including clinical practice, drug discovery and development in oncology and hematological malignancies. He is currently Chief Medical
View Full Bio
Rachelle Jacques
Director
Ms. Jacques is the former President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory
View Full Bio
John Jenkins, M.D.
Director
Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency
View Full Bio
Pete Salzmann, M.D., MBA
Director
Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member
View Full Bio
Winston Kung, MBA
Director
Winston Kung currently serves as Chief Financial Officer of Arrivent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics. Prior to Arrivent, Mr. Kung was Chief
View Full Bio
